Laura Joszt, MA

Laura Joszt headshot

Laura Joszt, MA, is the vice president of content for the managed care and pharmacy brands at MJH Life Sciences®, which includes The American Journal of Managed Care®, Managed Healthcare Executive®, Pharmacy Times®, and Drug Topics®. She has been with MJH Life Sciences since 2011.

Laura has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.

Articles by Laura Joszt, MA

AJMCtv® interviews let you catch up with experts on what’s new and important about changes in healthcare. The interviews provide insights from key decision makers-from the clinician to the health plan leader to the regulator. When every minute in your day matters, AJMCtv® interviews keep you informed. You can access the video clips at www.ajmc.com/interviews.

With the sustainability and affordability of the US healthcare system in dire straits, now is the time for collaboration on new payment models, explained chief executive officers from a health plan and an insurer during a general session on the second day of America’s Health Insurance Plans’ Institute & Expo, held June 7-9 in Austin, Texas.

The United States is only slightly halfway through its healthcare transformation, claimed Mike Leavitt, founder and partner of Leavitt Partners and the former governor of Utah, during a general session on the first day of America’s Health Insurance Plans Institute & Expo, held June 7-9, in Austin, Texas.

During a general session at America’s Health Insurance Plans’ Institute & Expo, held June 7-9 in Austin, Texas, Eric Topol, MD, explained the buzz behind precision medicine and why it is needed to combat the harms of imprecision in medicine.

Patients with cystic fibrosis face a lifetime of time-consuming treatment. There are new breakthrough therapies that not only treat symptoms of the disease, but also the underlying causes, which represents a source of hope for patients. However, barriers to treatment still stand in the way, according to a new white paper from the Cystic Fibrosis Engagement Network.

The notion of letting Medicare negotiate drug prices has been around for years, but has recently gained new traction under President Donald Trump. Panelists at the ISPOR 22nd Annual International Meeting, held May 20-24 in Boston, Massachusetts, discussed the complexities of allowing Medicare to negotiate prices and whether or not it would produce meaningful savings.

Is it possible to leverage social networks to influence response to treatment among an untreated population? During the second plenary at the ISPOR 22nd Annual International Meeting, held May 20-24 in Boston, Massachusetts, Nicholas Christakis, MD, PhD, of Yale University, described his research into social network interventions.

The United States healthcare system has to start spending less time fixing people and more time and money on reducing the need to fix them by getting to people earlier, according to panelists who participated in the Brookings Institution’s event “New Directions for Communities: How They Can Boost Neighborhood Health.”

The Senate has confirmed Scott Gottlieb, MD, for the position of FDA Commissioner. Gottlieb faced some criticism from Democrats for his close ties to the pharmaceutical industry, but he promised to recuse himself from any FDA decisions relating to some 20 companies and institutions for 1 year.

A day after House Republicans voted to pass legislation that repeals and replaces large parts of the Affordable Care Act, Avik Roy, Forbes opinion editor and president of the Foundation for Research on Equal Opportunity, outlined what Republicans are trying to fix. After his presentation, he joined a panel discussion on what impact the American Health Care Act will have.



Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo